Published in Medical Letter on the CDC and FDA, September 10th, 2006
Corautus had cash, cash equivalents and short-term investments of $22,813,000 as of June 30, 2006. Corautus expects that its existing capital resources will be sufficient to fund its current and planned operations through the end of the third quarter of 2007.
Revenues were $21,000 for the three months ended June 30, 2006 and 2005 and $42,000 for the six months ended June 30, 2006 and 2005, reflecting the amortization of a payment received from the sublicense of certain patents to Boston Scientific...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.